Why the study?
The failure of current obesity treatments prompted exploration of whether thermogenesis-affecting drugs exert different effects on classic brown versus beige adipose tissue.
Key points are not available for this paper at this time.
Comparison
Effects of thermogenesis-affecting drugs on classic brown versus beige adipose tissue
Design
Review
Subtype distinction in brown adipose tissue warrants cautious exploration in obesity trials; leaves open whether classic or beige activation yields superior metabolic benefits.
The failure of the fight against obesity makes us turn to new goals in its treatment. Now, brown adipose tissue has attracted attention as a promising target for the treatment of obesity and associated metabolic disorders such as insulin resistance, dyslipidemia, and glucose tolerance disorders. Meanwhile, the expansion of our knowledge has led to awareness about two rather different subtypes: classic brown and beige (inducible brown) adipose tissue. These subtypes have different origin, differences in the expression of individual genes but also a lot in common. Both tissues are thermogenic, which means that, by increasing energy consumption, they can improve their balance with excess intake. Both tissues are activated in response to specific inducers (cold, beta-adrenergic receptor activation, certain food and drugs), but beige adipose tissue transdifferentiates back into white adipose tissue after the cessation of inducing action, while classic brown adipose tissue persists, but its activity decreases. In this review, we attempted to understand whether there are differences in the effects of different groups of thermogenesis-affecting drugs on these tissues. The analysis showed that this area of research is rather sparse and requires close attention in further studies.
No takes yet. Share an insight, caveat, or question.
Kononova et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: